for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novacyt SA

NCYT.L

Latest Trade

302.50GBp

Change

-5.00(-1.63%)

Volume

222,222

Today's Range

--

 - 

--

52 Week Range

6.03

 - 

529.00

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Novacyt To Launch More COVID-19 Testing Products

July 27 (Reuters) - Novacyt SA <ALNOV.PA>::NOVACYT S.A. RESEARCH AND DEVELOPMENT UPDATE.LAUNCH OF NEAR-PATIENT (MOBILE) TESTING, WHICH COMPRISES NOVACYT'S COVID-19 TEST, DIRECT-TO-PCR RNA EXTRACTION KIT (EXSIG™ DIRECT), AND Q16 AND Q32 INSTRUMENTS.LAUNCH OF A SALIVA SAMPLING TYPE TO SUPPORT EASE OF PATIENT SAMPLING, LOWER LEVELS OF DISCOMFORT AND DEMONSTRATE MORE REPRODUCIBLE DATA.DEVELOPMENT OF A RESPIRATORY TESTING PANEL TO DIAGNOSE AND DISTINGUISH BETWEEN INFLUENZA A&B, RSV AND COVID-19.DEVELOPMENT, TOGETHER WITH A PARTNER, OF A SEROLOGY (ANTIBODY) TEST TO DETECT PAST INFECTION OF COVID-19. LAUNCH EXPECTED IN Q4 2020.LAUNCH OF THIS NEW PRODUCT EXPECTED DURING SEPTEMBER 2020 FOR 2020/21 FLU SEASON IN NORTHERN HEMISPHERE.DEVELOPMENT OF A TWO-GENE TEST TO ADDRESS MARKETS EMPLOYING THIS TESTING APPROACH. LAUNCH EXPECTED NO LATER THAN SEPTEMBER 2020.DEVELOPMENT OF A TWO-GENE TEST TO ADDRESS MARKETS EMPLOYING THIS TESTING APPROACH WITH LAUNCH EXPECTED NO LATER THAN SEPTEMBER 2020.DEVELOPMENT, TOGETHER WITH A PARTNER, OF A SEROLOGY (ANTIBODY) TEST TO DETECT PAST INFECTION OF COVID-19 WITH LAUNCH EXPECTED IN Q4 2020.

Novacyt Contributes To Clinical Trial With Near-Patient Testing System

July 22 (Reuters) - NOVACYT SA <ALNOV.PA>::NOVACYT S.A. ("NOVACYT", THE "COMPANY" OR THE “GROUP”): 2,000 PATIENT CLINICAL TRIAL USING NOVACYT’S NEAR-PATIENT TESTING SYSTEM INITIATED IN LONDON CARE HOMES.STUDY IS INVESTIGATING WHETHER DAILY COVID-19 TESTING REDUCES INFECTION RATE, MORBIDITY AND MORTALITY IN HIGH-RISK CARE HOME POPULATION.INITIATION OF A CLINICAL TRIAL BY QUEEN MARY UNIVERSITY OF LONDON USING COMPANY'S INNOVATIVE NEAR-PATIENT TESTING SYSTEM.RANDOMISED CLINICAL TRIAL IS RECRUITING UP TO 2,000 RESIDENTS IN 50 CARE HOMES ACROSS EAST LONDON.WE BELIEVE OUR NEW SYSTEM INCREASES NUMBER OF OPTIONS AVAILABLE FOR RAPID AND RELIABLE COVID-19 TESTING OUTSIDE OF CENTRALISED CARE AND WE EXPECT TO LAUNCH SYSTEM BY END OF JULY 2020 - CEO.

Novacyt SA Estimates EBITDA Profitability Over EUR45 Mln For HY

July 13 (Reuters) - Novacyt SA <ALNOV.PA>::NOVACYT SA - UNAUDITED REVENUE FOR FIRST HALF OF 2020 INCREASED OVER 900% TO EUR 72.4 MILLION (£63.3 MILLION).NOVACYT SA - COMPANY ANTICIPATES REVENUE FOR SECOND HALF OF YEAR TO BE GREATER THAN FIRST HALF OF YEAR.NOVACYT SA - DEMAND FOR COMPANY'S COVID-19 TEST REMAINS STRONG, WITH JUNE SALES OF EUR 25.4 MILLION (£22.5 MILLION).NOVACYT SA - FOR HALF YEAR, GROUP ESTIMATES EBITDA PROFITABILITY OVER EUR 45 MILLION (£41 MILLION).

Novacyt: to settle debts with Harbert European Growth Capital and Vatel

June 3 (Reuters) - Novacyt SA <ALNOV.PA>::NOVACYT S.A.: EARLY SETTLEMENT OF TERM LOAN AND CONVERTIBLE BOND FACILITY REMOVES LONG TERM DEBT.WILL SETTLE ALL OUTSTANDING DEBT OBLIGATIONS WITH HARBERT EUROPEAN GROWTH CAPITAL ("HEGC") AND VATEL CAPITAL SAS ("VATEL")..UNDER ARRANGEMENTS, NOVACYT WILL CLEAR ITS DEBT OBLIGATIONS WITH HEGC AND VATEL BEFORE END OF JUNE 2020.IN DOING SO, IT WILL SETTLE A TOTAL OF EUR 7.0M OF PRINCIPAL DEBT PROVIDED BY TWO LENDERS..AS OF 2 JUNE 2020, PRIOR TO PAYMENT TO HEGC, GROUP HAD A NET CASH BALANCE OF EUR 25M (CASH AS AT 31 DECEMBER 2019 OF EUR 1.8M)..

Novacyt Sees More COVID-19 Related Sales In H2

June 2 (Reuters) - Novacyt Sa <ALNOV.PA>::NOVACYT CORONAVIRUS UPDATE.AS OF 1 JUNE 2020, SALES OF PRIMERDESIGN COVID-19 TEST ARE EUR 45 MILLION (£40 MILLION).IN ADDITION, PRIMERDESIGN HAS RECEIVED ORDERS FOR, OR BEEN CONTRACTED TO DELIVER, A FURTHER EUR 90 MILLION (£80 MILLION) OF ITS COVID-19 TEST.THEREFORE, CURRENTLY TOTAL SALES AND CONFIRMED ORDERS ARE EUR 135 MILLION (£120 MILLION).DURING SECOND HALF OF YEAR, ADDITIONAL COVID-19 RELATED SALES ARE EXPECTED FROM COMPANY'S NEW PRODUCTS.NOVACYT IS NOW SELLING ITS COVID-19 TEST INTO MORE THAN 130 COUNTRIES, WITH TOP TWO COUNTRIES BEING UK AND GERMANY.NOVACYT IS ALSO PLEASED WITH PROGRESS IT IS MAKING IN US MARKET AND EXPECTS TO UPDATE MARKET IN DUE COURSE.ZIMBABWE'S MINISTRY OF HEALTH AND CHILD CARE HAS AWARDED PRIMERDESIGN WITH A CONTRACT FOR SUPPLY OF 1.5 MILLION TESTS.FRENCH REGULATORY BODY HAS NOT APPROVED PRIMERDESIGN'S COVID-19 TEST FOR REIMBURSEMENT IN FRANCE.NOVACYT HAS SECURED REGISTRATIONS AND REGULATORY APPROVALS IN FOLLOWING NEW MARKETS FOR ITS COVID-19 TEST: PANAMA, ECUADOR, COLOMBIA, PERU, PARAGUAY AND UAE.CONTINUE TO OFFER TEST FOR PRIVATE PATIENT TESTING AND EVALUATE NEW WAYS OF SUPPORTING FRENCH MARKET.

Novacyt FY Net Loss Widens To 6.6 Million Euros

May 14 (Reuters) - NOVACYT SA <ALNOV.PA>::FY NET LOSS -6.6 MILLION EUR VERSUS -4.7 MILLION EUR LOSS YEAR AGO.FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019 AND OUTLOOK FOR 2020.EXPECT 2020 TO BE TRANSFORMATIONAL FOR BUSINESS IN ALMOST EVERY WAY.CONTINUED SIGNIFICANT DEMAND FOR COVID-19 TEST EXPECTED TO BE TRANSFORMATIONAL FOR GROUP IN 2020.DIRECTORS BELIEVE SIGNIFICANT DEMAND FOR COMPANY'S COVID-19 TEST WILL CONTINUE THROUGH TO END OF YEAR, AND MAY EXTEND WELL INTO 2021, AS GLOBAL DEMAND FOR COVID-19 TESTING CONTINUES TO INCREASE.FOUR MONTHS TO END OF APRIL 2020, GROUP ACHIEVED AN EBITDA MARGIN IN EXCESS OF 50% DRIVEN BY SUCCESS OF COVID-19 TEST.AND AS OF END OF APRIL 2020, GROUP HAD A NET CASH BALANCE OF EUR 9.2M.CASH AT YEAR END OF EUR 1.8M (£1.5M) COMPARED WITH EUR 1.1M (£1.0M) IN 2018.ADJUSTED EBITDA OF EUR 0.2 MILLION IN 2019 COMPARED WITH EUR 0.6 MILLION IN 2018.COMPANY'S SIGNIFICANT INCREASE IN FINANCIAL PERFORMANCE IS EXPECTED TO CONTINUE THROUGHOUT 2020.

Novacyt Contracted To Deliver Over 103 Million Euros Of COVID-19 Test

April 29 (Reuters) - NOVACYT SA <ALNOV.PA>::COVID-19 UPDATE AND NOTIFICATION OF FINAL RESULTS.AS OF 28 APRIL 2020, PRIMERDESIGN HAS SOLD, RECEIVED ORDERS FOR OR HAS BEEN CONTRACTED TO DELIVER OVER £90 MILLION (EUR 103 MILLION) OF ITS COVID-19 TEST.NOVACYT IS NOW SUPPLYING ITS COVID-19 TEST TO MORE THAN 100 COUNTRIES.CONTINUES TO INCREASE ITS SALES LEVEL INTO U.S. MARKET AND IS EVALUATING POTENTIAL OPTIONS TO FURTHER EXPAND ITS PRESENCE THERE.

Novacyt S.A. Says Signed Manufacturing Partnership Agreements For Its Covid-19 Test

April 15 (Reuters) - Novacyt SA <ALNOV.PA>::NOVACYT S.A. - MANUFACTURING AND RESEARCH AND DEVELOPMENT UPDATE FOR COVID-19 TEST.NOVACYT SA - IS WORKING TO FURTHER INCREASE MANUFACTURING CAPACITY.NOVACYT SA - HAS SIGNED MANUFACTURING PARTNERSHIP AGREEMENTS WITH BIOPHARMA PROCESS SERVICES LTD AND BIOFORTUNA LIMITED.NOVACYT SA - EXPECTS, OVER NEXT THREE MONTHS, TO INCREASE PRODUCTION OF TEST TO ABOUT EIGHT MILLION TESTS PER MONTH.NOVACYT SA - IS ALSO IN DISCUSSIONS WITH FURTHER POTENTIAL UK-BASED MANUFACTURING PARTNERS.NOVACYT SA - IS ALSO EXPANDING ITS KEY RAW MATERIAL SUPPLIER BASE FOR ITS COVID-19 TEST.NOVACYT SA - EXPECTS TO HAVE NEW EXTRACTION TECHNOLOGY AVAILABLE TO LAUNCH IN MAY 2020.NOVACYT SA - GOT EMERGENCY USE APPROVAL FOR TEST FROM FEDERAL DRUG AGENCY OF SAUDI ARABIA.NOVACYT SA - GOT EMERGENCY USE APPROVAL FOR TEST FROM NATIONAL AGENCY OF DRUG AND FOOD CONTROL OF REPUBLIC OF INDONESIA.NOVACYT SA - ALSO RECEIVED IMPORT APPROVAL FROM DRUGS CONTROLLER GENERAL OF INDIA.

Novacyt's COVID-19 Test Eligible For WHO Emergency Use Listing

April 8 (Reuters) - Novacyt SA <ALNOV.PA>::NOVACYT COVID-19 TEST ELIGIBLE FOR WHO EMERGENCY USE LISTING.TEST FOR COVID-19 (Z-PATH COVID-19-CE IVD) HAS BEEN LISTED AS ELIGIBLE FOR WORLD HEALTH ORGANIZATION.TEST WILL BE ELIGIBLE FOR PROCUREMENT FOR ONE YEAR, UNLESS CIRCUMSTANCES DICTATE OTHERWISE.TEST HAS BEEN DEVELOPED BY NOVACYT'S MOLECULAR DIAGNOSTICS DIVISION, PRIMERDESIGN, BASED IN SOUTHAMPTON, UK.

CNR Of Institut Pasteur Has Approved COVID-19 Test Of Novacyt

April 6 (Reuters) - Novacyt SA <ALNOV.PA>::COVID-19 DIAGNOSTIC REGULATORY UPDATE.CNR (CENTRE NATIONAL DE RÉFÉRENCE DES VIRUS DES INFECTIONS RESPIRATOIRES (DONT LA GRIPPE)) OF INSTITUT PASTEUR, HAS APPROVED ITS COVID-19 TEST.COMPANY'S CE-MARK TEST IS AVAILABLE FOR IMMEDIATE DISTRIBUTION INTO FRENCH MARKET.2 APRIL 2020, NOVACYT ALSO RECEIVED APPROVAL FOR ITS COVID-19 TEST FROM MINISTRY OF HEALTH IN THAILAND.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up